Enveric Biosciences, Inc.

For the period ended Dec 31, 2024. Filed Mar 28, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 28, 2025

ENVB$1.51+4.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

	For the Years Ended December 31,
	2024	2023
Operating expenses
General and administrative	$6,453,505	$8,852,021
Research and development	2,841,272	7,252,437
Depreciation and amortization	337,489	343,982
Total operating expenses	9,632,266	16,448,440
Loss from operations	(9,632,266)	(16,448,440)
Other income (expense)
Inducement expense, net	—	(1,848,235)
Change in fair value of warrant liabilities	24,370	94,396
Change in fair value of investment option liability	21,620	208,752
Change in fair value of derivative liability	—	727,000
Other income	20,000	—
Interest income, net	219	3,708
Total other income (expense)	66,209	(814,379)
Net loss before income taxes	(9,566,057)	(17,262,819)
Income tax expense	(8,930)	(28,913)
Net loss	(9,574,987)	(17,291,732)
Less preferred dividends attributable to non-controlling interest	—	19,041
Less deemed dividends attributable to accretion of embedded derivative at redemption value	—	147,988
Net loss attributable to shareholders	(9,574,987)	(17,458,761)
Other comprehensive loss
Foreign currency translation	(24,768)	(33,015)
Comprehensive loss	$(9,599,755)	$(17,491,776)
Net loss per share - basic and diluted	$(19.04)	$(121.29)
Weighted average shares outstanding, basic and diluted	502,900	143,938

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.